Articles
Time to put Pharma 3.0 into action!

Time to put Pharma 3.0 into action!

Phil Golz shares with pharmaphorum around why he would like to see less talk and more action around moving into the era of Pharma 3.0. Phil Golz works within GSK to identify existing and future areas of focus for pharmaceutical innovation. He speaks with pharmaphorum...

Articles
German life science part two: difficult times, unusual strategies

German life science part two: difficult times, unusual strat...

In part two, Mariana Brea-Krueger discusses new strategies that biotech and pharma will need to consider in order to survive the current pricing squeeze. Germany leads the way in new legislation to curb cost in its national health insurance system (GKV). Demographically, the aging...

Articles
Spotlight on... HIV and AIDS

Spotlight on... HIV and AIDS

This month’s spotlight is on HIV and AIDS – we speak with Dr Michael Brady to find out how pharma and the UK government are supporting patients in this disease area. By the end of 2010, an estimated 34 million people were living with HIV worldwide – up 17% from the...

Sales & Marketing

Digital

Market Access

Newsletters and Deep Dive
digital magazine

Oncology

Oncology
Cancer cell

Building a Phase I oncology centre

The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.

Patients

R&D